These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10121421)

  • 41. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
    Nyvad O; Danielsen H; Madsen S
    Lancet; 1994 Nov; 344(8932):1305-6. PubMed ID: 7968018
    [No Abstract]   [Full Text] [Related]  

  • 42. Case study of the anemic patient: epoetin alfa--focus on erythrokinetics.
    Chmielewski CM
    ANNA J; 1995 Aug; 22(4):420-3. PubMed ID: 7654091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy.
    Cotter D; Thamer M; Zhang Y
    Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526
    [No Abstract]   [Full Text] [Related]  

  • 44. Developing an epoetin alfa medication protocol to improve patient care and foster collaboration.
    Shanahan M; Walton S
    ANNA J; 1995 Oct; 22(5):471-6. PubMed ID: 7487190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential cost savings of erythropoietin administration in end-stage renal disease.
    Hynes DM; Stroupe KT; Greer JW; Reda DJ; Frankenfield DL; Kaufman JS; Henderson WG; Owen WF; Rocco MV; Wish JB; Kang J; Feussner JR
    Am J Med; 2002 Feb; 112(3):169-75. PubMed ID: 11893342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.
    Harris DC
    Pharmacoeconomics; 1994 Jan; 5(1):18-28. PubMed ID: 10146863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vascular access thrombosis in epoetin alfa therapy.
    Leonard DK
    ANNA J; 1991 Aug; 18(4):371-6; discussion 377. PubMed ID: 1872636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epoetin--an important advance.
    Drug Ther Bull; 1992 Apr; 30(8):29-32. PubMed ID: 1591993
    [No Abstract]   [Full Text] [Related]  

  • 49. Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98.
    Greer JW; Milam RA; Eggers PW
    Health Care Financ Rev; 1999; 20(3):55-62. PubMed ID: 10558020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The safety of epoetin-alpha: results of clinical trials in the United States.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    Contrib Nephrol; 1991; 88():72-80. PubMed ID: 2040198
    [No Abstract]   [Full Text] [Related]  

  • 51. Reconciling decision models with the real world. An application to anaemia of renal failure.
    Shih YC; Kauf TL
    Pharmacoeconomics; 1999 May; 15(5):481-93. PubMed ID: 10537965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of epoetin for anemia in chronic renal failure.
    Flamm CR; Aronson N; Bohn R; Finkelstein B; Piper M; Seidenfeld J; Bonnell CJ; Carter M; Gere M; Ziegler KM
    Evid Rep Technol Assess (Summ); 2001 Aug; (29):1-8. PubMed ID: 11572067
    [No Abstract]   [Full Text] [Related]  

  • 53. A cost-effectiveness analysis of epoetin usage for patients with AIDS.
    Cantor SB; Carson RW; Spann SJ
    Pharmacoeconomics; 1993 Mar; 3(3):244-9. PubMed ID: 10146947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug usage evaluation of epoetin in chronic renal failure.
    Mason NA; Iacobellis DP
    Hosp Formul; 1992 Sep; 27(9):928-32, 937-8. PubMed ID: 10121421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A; Spasovski G; Zafirov D; Polenakovic M
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G;
    G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.